Pharmaceutical compositions for intraocular administration and methods for fabricating thereof

Abstract

Pharmaceutical compositions for intraocular injection are described, the compositions consisting essentially of a therapeutically effective quantity of an anti-bacterial agent (such as moxifloxacin), a therapeutically effective quantity of an anti-inflammatory agent (such as prednisolone), at least one pharmaceutically acceptable excipient and a pharmaceutically acceptable carrier. Methods for fabricating the compositions and using them for intraocular injections are also described.

What is claimed is: 
     
         1 . A method for treating an ophthalmological disease, condition or pathology in a mammalian subject in need of such treatment comprising delivering to the subject a composition comprising:
 (a) a therapeutic component consisting essentially of:
 (a1) a therapeutically effective quantity of an anti-bacterial agent independently selected from the group consisting of quinolone, a fluorinated quinolone and pharmaceutically acceptable salts, hydrates, solvates or N-oxides thereof; and 
 (a2) a therapeutically effective quantity of a corticosteroid independently selected from the group consisting of prednisone, prednisolone, methylprednisone, corticol, cortisone, fluorocortisone, deoxycorticosterone acetate, aldosterone, budesonide, derivatives or analogs thereof and pharmaceutically acceptable salts, hydrates, solvates, ethers, esters, acetals and ketals thereof; 
   (b) at least one pharmaceutically acceptable solubilizing and suspending agent selected from the group consisting of non-ionic polyoxyethylene-polyoxypropylene block copolymers; and   (c) optionally, a pharmaceutically acceptable carrier therefor,   
       wherein the method of delivery is selected from the group consisting of intravitreal injection, intraocular intracameral injection, intra-lesional injection, intra-articular injection, subconjunctival injection, sub-tenon injection, delivery via eye drops, delivery via spray and intra-canalicular delivery, to treat the ophthalmological disease, condition or pathology thereby. 
     
     
         2 . The method of  claim 1 , wherein the mammalian subject is selected from the group consisting of a human, a cat, a dog, another pet, a wild animal and a farm animal. 
     
     
         3 . The method of  claim 1 , wherein the method of delivery is delivery via eye drops. 
     
     
         4 . A method for treating an ophthalmological disease, condition or pathology in a mammalian subject in need of such treatment comprising:
 (a) performing a keratomileusis surgery on the subject; and   (b) administering to the subject a composition comprising:
 a. a therapeutic component consisting essentially of:
 a1. a therapeutically effective quantity of an anti-bacterial agent independently selected from the group consisting of quinolone, a fluorinated quinolone and pharmaceutically acceptable salts, hydrates, solvates or N-oxides thereof; and 
 a2. a therapeutically effective quantity of a corticosteroid independently selected from the group consisting of prednisone, prednisolone, methylprednisone, corticol, cortisone, fluorocortisone, deoxycorticosterone acetate, aldosterone, budesonide, derivatives or analogs thereof and pharmaceutically acceptable salts, hydrates, solvates, ethers, esters, acetals and ketals thereof; 
 
 b. at least one pharmaceutically acceptable solubilizing and suspending agent selected from the group consisting of non-ionic polyoxyethylene-polyoxypropylene block copolymers; and 
 c. optionally, a pharmaceutically acceptable carrier therefor. 
   
     
     
         5 . The method of  claim 4 , wherein the keratomileusis surgery is selected from the group consisting of laser-assisted in situ surgery (LASIK), photorefractive keratectomy (PRK), laser-assisted sub-epithelial keratectomy (LASEK), corneal ring segments, corneal cross linking, refractive corneal inlays and corneal lenticular surgery. 
     
     
         6 . The method of  claim 5 , wherein the keratomileusis surgery is LASIK surgery. 
     
     
         7 . The method of  claim 4 , wherein the composition is administered via drops after the surgery.